Attorney's Docket No.: 14875-147US1 / C1-A0226P-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Takaki Koga et al.

Art Unit : 1645

Filed

Serial No.: 10/542,682

Examiner: Unknown Conf. No.: 5413

Title

: December 14, 2005 : ANTI-PCI NEUTRALIZING ANTIBODIES

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Copies of the references are enclosed. A copy of a Supplementary Partial European Search Report from a counterpart application (EP 04 70 3509) is also enclosed.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 14875-147US1.

Respectfully submitted,

Date:

Jianming Hao, Ph.D.

Reg. No. 54,694

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110

Telephone: (617) 542-5070 Facsimile: (617) 542-8906

21623698.doc

Sheet	1	of	1	
SHOOL	1	Οī		

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-147US1	Application No. 10/542,682	
Supplemental Information Disclosure Statement by Applicant		Applicant Takaki Koga et al.		
(Use several sh	neets if necessary)	Filing Date	Group Art Unit	
(37 CFR \$1.98(b))		December 14, 2005	1645	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
	AB							

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	D	Document		
	AC	Ewert et al., "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering," <i>Methods</i> ,		
		34:184-199 (2004)		
	AD	Griffin et al., "Activated Protein C: Potential Therapy for Severe Sepsis, Thrombosis, and Stroke," Semin. Hematol., 39:197-205 (2002)		
		Gruber et al., "Inhibition of Thrombus Formation by Activated Recombinant Protein C in a Primate		
	AE	Model of Arterial Thrombosis," <i>Circulation</i> , 82:578-585 (1990)		
	AF	Heeb et al., "Activation and Complexation of Protein C and Cleavage and Decrease of Protein S in		
		Plasma of Patients With Intravascular Coagulation," Blood, 73:455-461 (1989)		
	AG	Laurell et al., "Monoclonal Antibodies Against the Heparin-Dependent Protein C Inhibitor Suitable for Inhibitor Purification and Assay of Inhibitor Complexes," <i>Thromb. Haemost.</i> , 60:334-339 (1988)		
	АН	Meijers et al., "Protein C inhibitor (plasminogen activator inhibitor-3) and the risk of venous thrombosis," <i>Br. J. Haematol.</i> , 118:604-609 (2002)		

Examiner Signature	Date Considered
EVANUATED Interest of a few and a fe	